Atreca (NASDAQ:BCEL – Get Rating) and Mustang Bio (NASDAQ:MBIO – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation and institutional ownership. Institutional & Insider Ownership 40.2% of Atreca shares are owned […]
HC Wainwright reiterated their buy rating on shares of Atreca (NASDAQ:BCEL – Get Rating) in a report released on Thursday, Benzinga reports. HC Wainwright currently has a $25.00 price objective on the stock. A number of other analysts have also commented on BCEL. Wedbush reissued an outperform rating and set a $4.00 price target on […]
EF Hutton Acquisition Co. I reissued their buy rating on shares of Atreca (NASDAQ:BCEL – Get Rating) in a research report released on Thursday morning, Benzinga reports. EF Hutton Acquisition Co. I currently has a $10.00 target price on the stock. Several other equities research analysts have also recently issued reports on the stock. Wedbush […]
Atreca, Inc. (NASDAQ:BCEL – Get Rating) – Analysts at Jefferies Financial Group issued their Q1 2023 EPS estimates for Atreca in a research note issued on Wednesday, March 29th. Jefferies Financial Group analyst R. Song anticipates that the company will post earnings per share of ($0.54) for the quarter. The consensus estimate for Atreca’s current […]
Atreca, Inc. (NASDAQ:BCEL – Get Rating) – Research analysts at Wedbush issued their Q1 2024 earnings estimates for shares of Atreca in a note issued to investors on Thursday, March 30th. Wedbush analyst R. Driscoll anticipates that the company will earn ($0.42) per share for the quarter. Wedbush currently has a “Outperform” rating and a […]